Regional disparities in cancer survival in Iran: Insight from a National Surveillance of Cancer Survival in Iran (IRANCANSURV)

Saeed Nemati; Elnaz Saeedi; Fereshte Lotfi; Azin Nahvijou; Habbiballah Pirnejad; Maria Cheraghi; Abbas Rezaeianzadeh; Roya Dolatkhah; Azam Bazarafshan; Arash Golpazir; Majid Yaghoobi-Ashrafi; Sepideh Abdi; Saba Alvand; Zahra Ravankhah; Elham Mohebbi; Ardeshir Khosravi; Arash Etemadi; Mahdi Sheikh; Gholamreza Roshandel; Ali Ghanbari-Motlagh; Elham Partovipour; Farid Najafi; Reza Malekzadeh; Mohammad Ali Mohagheghi; Kazem Zendehdel

doi:10.1016/j.canep.2023.102378

Regional disparities in cancer survival in Iran: Insight from a National Surveillance of Cancer Survival in Iran (IRANCANSURV)

Saeed Nemati, Elnaz Saeedi, Fereshte Lotfi, Azin Nahvijou, Habbiballah Pirnejad, Maria Cheraghi, Abbas Rezaeianzadeh, Roya Dolatkhah, Azam Bazarafshan, Arash Golpazir, Majid Yaghoobi-Ashrafi, Sepideh Abdi, Saba Alvand, Zahra Ravankhah, Elham Mohebbi, Ardeshir Khosravi, Arash Etemadi, Mahdi Sheikh, Gholamreza Roshandel, Ali Ghanbari-MotlaghElham Partovipour, Farid Najafi, Reza Malekzadeh, Mohammad Ali Mohagheghi, Kazem Zendehdel^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

Abstract

BACKGROUND AND OBJECTIVES: We aimed to investigate geographical disparity in cancer survival in 9 provincial population-based cancer registries in Iran from 2015 to 2016.

MATERIAL AND METHOD: In the current study, data from 90,862 adult patients (aged >15 years) diagnosed with cancer were retrieved from 9 population-based cancer registries across Iran. Five-year survival rates were estimated by applying relative survival approaches. We also applied the international cancer survival standard weights for age standardization. Finally, we calculated the excess hazard ratio (EHR) for each province adjusted for age, sex, and cancer sites to estimate the excess hazard ratio of mortality compared to the capital province (Tehran).

RESULTS: The largest gap in survival was observed in more curable cancer types, including melanoma (41.4%), ovary (32.3%), cervix (35.0%), prostate (26.7%), and rectum (21.4%), while the observed geographical disparity in lethal cancers such as lung, brain, stomach, and pancreas was less than 15%. Compared to Tehran, we found the highest excess hazard of death in Western Azerbaijan (EHR=1.60, 95% CI 1.51, 1.65), Kermanshah (EHR=1.52, 95% CI=1.44, 1.61), and Kerman (EHR=1.46, 95% CI=1.38, 1.53). The hazard ratio of death was almost identical in Isfahan (EHR=1.04, 95% CI=1.03, 1.06) and Tehran provinces.

CONCLUSION: Provinces with higher HDI had better survival rates. IRANCANSURV study showed regional disparities in cancer survival in Iran. Cancer patients in provinces with a higher Human Development Index (HDI) had a higher survival rate and lived longer compared to the patients in provinces with medium and low HDI regions.

Original language	English
Article number	102378
Journal	Cancer Epidemiology
Volume	85
Early online date	23 May 2023
DOIs	https://doi.org/10.1016/j.canep.2023.102378
Publication status	Published - Aug 2023
Externally published	Yes

Bibliographical note

Funding Information: This study was financially supported by Tehran University of Medical Sciences, Iran (Grant No. 96-03-159-36043 ).

Publisher Copyright: © 2023 Elsevier Ltd

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.canep.2023.102378

Cite this

Nemati, S., Saeedi, E., Lotfi, F., Nahvijou, A., Pirnejad, H., Cheraghi, M., Rezaeianzadeh, A., Dolatkhah, R., Bazarafshan, A., Golpazir, A., Yaghoobi-Ashrafi, M., Abdi, S., Alvand, S., Ravankhah, Z., Mohebbi, E., Khosravi, A., Etemadi, A., Sheikh, M., Roshandel, G., ... Zendehdel, K. (2023). Regional disparities in cancer survival in Iran: Insight from a National Surveillance of Cancer Survival in Iran (IRANCANSURV). Cancer Epidemiology, 85, Article 102378. https://doi.org/10.1016/j.canep.2023.102378

@article{2b0fa1a9102342f08062a4c026d07902,

title = "Regional disparities in cancer survival in Iran: Insight from a National Surveillance of Cancer Survival in Iran (IRANCANSURV)",

abstract = "BACKGROUND AND OBJECTIVES: We aimed to investigate geographical disparity in cancer survival in 9 provincial population-based cancer registries in Iran from 2015 to 2016.MATERIAL AND METHOD: In the current study, data from 90,862 adult patients (aged >15 years) diagnosed with cancer were retrieved from 9 population-based cancer registries across Iran. Five-year survival rates were estimated by applying relative survival approaches. We also applied the international cancer survival standard weights for age standardization. Finally, we calculated the excess hazard ratio (EHR) for each province adjusted for age, sex, and cancer sites to estimate the excess hazard ratio of mortality compared to the capital province (Tehran).RESULTS: The largest gap in survival was observed in more curable cancer types, including melanoma (41.4\%), ovary (32.3\%), cervix (35.0\%), prostate (26.7\%), and rectum (21.4\%), while the observed geographical disparity in lethal cancers such as lung, brain, stomach, and pancreas was less than 15\%. Compared to Tehran, we found the highest excess hazard of death in Western Azerbaijan (EHR=1.60, 95\% CI 1.51, 1.65), Kermanshah (EHR=1.52, 95\% CI=1.44, 1.61), and Kerman (EHR=1.46, 95\% CI=1.38, 1.53). The hazard ratio of death was almost identical in Isfahan (EHR=1.04, 95\% CI=1.03, 1.06) and Tehran provinces.CONCLUSION: Provinces with higher HDI had better survival rates. IRANCANSURV study showed regional disparities in cancer survival in Iran. Cancer patients in provinces with a higher Human Development Index (HDI) had a higher survival rate and lived longer compared to the patients in provinces with medium and low HDI regions.",

author = "Saeed Nemati and Elnaz Saeedi and Fereshte Lotfi and Azin Nahvijou and Habbiballah Pirnejad and Maria Cheraghi and Abbas Rezaeianzadeh and Roya Dolatkhah and Azam Bazarafshan and Arash Golpazir and Majid Yaghoobi-Ashrafi and Sepideh Abdi and Saba Alvand and Zahra Ravankhah and Elham Mohebbi and Ardeshir Khosravi and Arash Etemadi and Mahdi Sheikh and Gholamreza Roshandel and Ali Ghanbari-Motlagh and Elham Partovipour and Farid Najafi and Reza Malekzadeh and Mohagheghi, \{Mohammad Ali\} and Kazem Zendehdel",

note = "Funding Information: This study was financially supported by Tehran University of Medical Sciences, Iran (Grant No. 96-03-159-36043 ). Publisher Copyright: {\textcopyright} 2023 Elsevier Ltd",

year = "2023",

month = aug,

doi = "10.1016/j.canep.2023.102378",

language = "English",

volume = "85",

journal = "Cancer Epidemiology",

issn = "1877-7821",

publisher = "Elsevier Ltd.",

}

Nemati, S, Saeedi, E, Lotfi, F, Nahvijou, A, Pirnejad, H, Cheraghi, M, Rezaeianzadeh, A, Dolatkhah, R, Bazarafshan, A, Golpazir, A, Yaghoobi-Ashrafi, M, Abdi, S, Alvand, S, Ravankhah, Z, Mohebbi, E, Khosravi, A, Etemadi, A, Sheikh, M, Roshandel, G, Ghanbari-Motlagh, A, Partovipour, E, Najafi, F, Malekzadeh, R, Mohagheghi, MA & Zendehdel, K 2023, 'Regional disparities in cancer survival in Iran: Insight from a National Surveillance of Cancer Survival in Iran (IRANCANSURV)', Cancer Epidemiology, vol. 85, 102378. https://doi.org/10.1016/j.canep.2023.102378

TY - JOUR

T1 - Regional disparities in cancer survival in Iran

T2 - Insight from a National Surveillance of Cancer Survival in Iran (IRANCANSURV)

AU - Nemati, Saeed

AU - Saeedi, Elnaz

AU - Lotfi, Fereshte

AU - Nahvijou, Azin

AU - Pirnejad, Habbiballah

AU - Cheraghi, Maria

AU - Rezaeianzadeh, Abbas

AU - Dolatkhah, Roya

AU - Bazarafshan, Azam

AU - Golpazir, Arash

AU - Yaghoobi-Ashrafi, Majid

AU - Abdi, Sepideh

AU - Alvand, Saba

AU - Ravankhah, Zahra

AU - Mohebbi, Elham

AU - Khosravi, Ardeshir

AU - Etemadi, Arash

AU - Sheikh, Mahdi

AU - Roshandel, Gholamreza

AU - Ghanbari-Motlagh, Ali

AU - Partovipour, Elham

AU - Najafi, Farid

AU - Malekzadeh, Reza

AU - Mohagheghi, Mohammad Ali

AU - Zendehdel, Kazem

PY - 2023/8

Y1 - 2023/8

N2 - BACKGROUND AND OBJECTIVES: We aimed to investigate geographical disparity in cancer survival in 9 provincial population-based cancer registries in Iran from 2015 to 2016.MATERIAL AND METHOD: In the current study, data from 90,862 adult patients (aged >15 years) diagnosed with cancer were retrieved from 9 population-based cancer registries across Iran. Five-year survival rates were estimated by applying relative survival approaches. We also applied the international cancer survival standard weights for age standardization. Finally, we calculated the excess hazard ratio (EHR) for each province adjusted for age, sex, and cancer sites to estimate the excess hazard ratio of mortality compared to the capital province (Tehran).RESULTS: The largest gap in survival was observed in more curable cancer types, including melanoma (41.4%), ovary (32.3%), cervix (35.0%), prostate (26.7%), and rectum (21.4%), while the observed geographical disparity in lethal cancers such as lung, brain, stomach, and pancreas was less than 15%. Compared to Tehran, we found the highest excess hazard of death in Western Azerbaijan (EHR=1.60, 95% CI 1.51, 1.65), Kermanshah (EHR=1.52, 95% CI=1.44, 1.61), and Kerman (EHR=1.46, 95% CI=1.38, 1.53). The hazard ratio of death was almost identical in Isfahan (EHR=1.04, 95% CI=1.03, 1.06) and Tehran provinces.CONCLUSION: Provinces with higher HDI had better survival rates. IRANCANSURV study showed regional disparities in cancer survival in Iran. Cancer patients in provinces with a higher Human Development Index (HDI) had a higher survival rate and lived longer compared to the patients in provinces with medium and low HDI regions.

AB - BACKGROUND AND OBJECTIVES: We aimed to investigate geographical disparity in cancer survival in 9 provincial population-based cancer registries in Iran from 2015 to 2016.MATERIAL AND METHOD: In the current study, data from 90,862 adult patients (aged >15 years) diagnosed with cancer were retrieved from 9 population-based cancer registries across Iran. Five-year survival rates were estimated by applying relative survival approaches. We also applied the international cancer survival standard weights for age standardization. Finally, we calculated the excess hazard ratio (EHR) for each province adjusted for age, sex, and cancer sites to estimate the excess hazard ratio of mortality compared to the capital province (Tehran).RESULTS: The largest gap in survival was observed in more curable cancer types, including melanoma (41.4%), ovary (32.3%), cervix (35.0%), prostate (26.7%), and rectum (21.4%), while the observed geographical disparity in lethal cancers such as lung, brain, stomach, and pancreas was less than 15%. Compared to Tehran, we found the highest excess hazard of death in Western Azerbaijan (EHR=1.60, 95% CI 1.51, 1.65), Kermanshah (EHR=1.52, 95% CI=1.44, 1.61), and Kerman (EHR=1.46, 95% CI=1.38, 1.53). The hazard ratio of death was almost identical in Isfahan (EHR=1.04, 95% CI=1.03, 1.06) and Tehran provinces.CONCLUSION: Provinces with higher HDI had better survival rates. IRANCANSURV study showed regional disparities in cancer survival in Iran. Cancer patients in provinces with a higher Human Development Index (HDI) had a higher survival rate and lived longer compared to the patients in provinces with medium and low HDI regions.

UR - https://www.scopus.com/pages/publications/85159878367

U2 - 10.1016/j.canep.2023.102378

DO - 10.1016/j.canep.2023.102378

M3 - Article

C2 - 37229955

SN - 1877-7821

VL - 85

JO - Cancer Epidemiology

JF - Cancer Epidemiology

M1 - 102378

ER -

Regional disparities in cancer survival in Iran: Insight from a National Surveillance of Cancer Survival in Iran (IRANCANSURV)

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this